Navigation Links
Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on February 14, 2013
Date:2/14/2013

alatin Technologies, Inc., such as statements about clinical trial results, potential actions by regulatory agencies including the FDA, regulatory plans, development programs, proposed indications for product candidates and market potential for product candidates, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause Palatin's actual results to be materially different from its historical results or from any results expressed or implied by such forward-looking statements.  Palatin's actual results may differ materially from those discussed in the forward-looking statements for reasons including, but not limited to, results of clinical trials, regulatory actions by the FDA and the need for regulatory approvals, Palatin's ability to fund development of its technology and establish and successfully complete clinical trials, the length of time and cost required to complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin's products, and other factors discussed in Palatin's periodic filings with the Securities and Exchange Commission. Palatin is not responsible for updating for events that occur after the date of this press release.

 PALATIN TECHNOLOGIES, INC.and SubsidiaryConsolidated Statements of Operations(unaudited)Three Months Ended December 31,Six Months Ended December 31,2012201120122011REVENUES:

$
,555$
,492$
,361$
38,709OPERATING EXPENSES:Research and development

2,445,7702,693,0674,78
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
2. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
3. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
4. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
5. Palatin Technologies, Inc. To Report Fiscal Year 2012 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2012
6. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
7. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
8. Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
9. Palatin Technologies, Inc. To Report Fiscal Year 2012 Fourth Quarter Results; Teleconference and Webcast to be held on September 11, 2012
10. Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
11. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... , Oct. 20, 2014  GenVec, Inc. (NASDAQ: ... P. Horovitz , Ph.D., from its board of directors effective ... in August 2003, and served as its chairman from June ... on the Nominating and Corporate Governance and Audit Committees of ... more than a decade of dedicated service to GenVec, and ...
(Date:10/20/2014)... Local veterinary surgeon, Dr. Tim McCarthy is seeking ... stem cells for dogs with osteoarthritis. Dr. McCarthy has ... clinical stem cell therapy for 7 years. The ultimate ... single injection of donor stem cells into one or ... inflammation in the treated joints. , Candidates for ...
(Date:10/19/2014)... 2014 The Asia-Pacific Bromine Market ... Asia-Pacific with analysis and forecast of revenue. , ... Bromine Market report, to get an idea of ... glimpse of the segmentation in the Asia-Pacific bromine ... figures. , http://www.micromarketmonitor.com/market/asia-pacific-bromine-6741503144.html , Bromine ...
(Date:10/19/2014)... The Asian Orthopedic braces and support systems report defines ... forecast of revenue. The Orthopedic braces and support systems market ... by 2018, at a developing CAGR of 4.4% from 2013 ... Orthopedic braces and support systems market, to get an idea ... of the segmentation of orthopedic braces and support systems market ...
Breaking Biology Technology:Zola P. Horovitz To Retire From GenVec Board 2Cascade Veterinary Referral Center Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 3The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 2The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 3The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 4
... CAMBRIDGE, Mass., Aug. 25 Peptimmune, Inc., ... a clinical trial to evaluate the safety, tolerability, pharmacokinetics, ... Multiple Sclerosis (SP-MS). PI-2301 is a novel peptide ... autoimmune diseases. , , The Phase ...
... CITY, Aug. 25 /PRNewswire-FirstCall/ - Medicago Inc. (TSX-V: ... effective and affordable vaccines based on proprietary manufacturing ... it has received clearance from Health Canada to ... its H5N1 Avian Influenza vaccine ("H5N1 vaccine"). Enrollment ...
... , SAN MATEO, Calif., Aug. 25 ... on developing and commercializing novel pain management therapies, today announced the ... a director and Audit Committee chairman, effective August 20, 2009. Mr. ... company focused on exploiting a novel, Nobel Prize winning method of ...
Cached Biology Technology:Peptimmune Completes Phase Ib Study of PI-2301 in Multiple Sclerosis Patients, and Presentation at ECTRIMS 2009 2Peptimmune Completes Phase Ib Study of PI-2301 in Multiple Sclerosis Patients, and Presentation at ECTRIMS 2009 3Medicago receives regulatory approval to begin human clinical testing with its avian flu pandemic vaccine 2Medicago receives regulatory approval to begin human clinical testing with its avian flu pandemic vaccine 3NeurogesX Appoints New Board Director and Audit Committee Chairman 2NeurogesX Appoints New Board Director and Audit Committee Chairman 3NeurogesX Appoints New Board Director and Audit Committee Chairman 4NeurogesX Appoints New Board Director and Audit Committee Chairman 5
(Date:10/18/2014)... for evaluation of suspected genetic conditions, whole-exome sequencing ... including detection of a number of rare genetic ... to a study appearing in JAMA . ... the American Society of Human Genetics annual meeting. ... regions of thousands of genes simultaneously using next-generation ...
(Date:10/17/2014)... from the University of Copenhagen have shown for the ... lungs of Cystic fibrosis patients, giving them the opportunity ... in chronic infections. , The study also discovered the ... (CF) patients was halted or slowed down by the ... all the oxygen and helped "suffocate" the bacteria, forcing ...
(Date:10/16/2014)... managers have a new synthesis of recent research findings ... forests in the two states. , The Ecology ... and Washington: A Synthesis of the Relevant Biophysical Science ... report published by the U.S. Forest Service,s Pacific Northwest ... from managers for a synthesis of the large body ...
Breaking Biology News(10 mins):Whole-exome sequencing shows potential as diagnostic tool 2Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2New report synthesizes best available science on management of moist mixed-conifer forests 2
... concept of "place" is increasingly being considered in the ... new resource that can help them recognize and respond ... their lives. Place-Based Conservation: Perspectives from the ... Northwest Research Station,s Linda Kruger, can help managers take ...
... in the blood often jump into action by multiplying ... off illness. But repeated infections and inflammation can deplete ... serious blood conditions such as cancer. Now, a team ... of Technology (Caltech) has found that, in mouse models, ...
... have developed a new method for delivering molecules into ... surface. The technique could find applications in drug delivery, ... a technique used to deliver molecules into cells ... caused by exposing them to electric pulses is ...
Cached Biology News:Keeping stem cells strong 2Single-cell transfection tool enables added control for biological studies 2
... The 2.0 network client/server version of Freezerworks ... workflow in high-volume labs and facilitates the sharing ... to share sample information. ... PowerPC (100MHz, PPC 601); 13 in monitor with ...
Polypropylene test tube racks, used in Thermo Forma's line of Test Tube Rack holders...
Mixing speed from 750-3200RPM, small vortexing orbit of1.0mm...
... ,5-Bromo-4-chloro-3-indoxyl-beta-D-galactopyranoside C 14 H 15 ... ,M.W.= 408.63 ,Assay: Greater than ... DMF) ,Biological Activity: Blue color with ... Agrees with theoretical values ,Thin Layer ...
Biology Products: